Laupacis Andreas
Institute for Clinical Evaluative Sciences, Division of General Internal Medicine, Sunnybrook and Women's Health Sciences Centre, and the Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Med Care. 2005 Jul;43(7 Suppl):15-9. doi: 10.1097/01.mlr.0000170002.90751.1a.
The Drug Quality and Therapeutics Committee (DQTC) and the Canadian Expert Drug Assessment Committee (CEDAC) make reimbursement recommendations to publicly funded outpatient drug plans in Ontario and Canada respectively. In this article, the organization and decision-making processes of these committees are described. Issues associated with these committees such as potential biases associated with pharmaceutical company submissions, transparency, restricted access programs, conditional listing, and price negotiation are discussed.
药物质量与治疗学委员会（DQTC）和加拿大专家药物评估委员会（CEDAC）分别向安大略省和加拿大的公共资助门诊药物计划提出报销建议。本文描述了这些委员会的组织和决策过程。讨论了与这些委员会相关的问题，如与制药公司提交材料相关的潜在偏见、透明度、受限获取计划、有条件上市和价格谈判等。
